Brookline analyst Kemp Dolliver downgraded Eyenovia (EYEN) to Hold from Buy without a price target following the CHAPERONE study failure.
Brookline analyst Kemp Dolliver downgraded Eyenovia (EYEN) to Hold from Buy without a price target following the CHAPERONE study failure.